Ziprasidone (Geodon)

What it treats

Ziprasidone is approved by the U.S. Food and Drug Administration to treat schizophrenia, to treat acute manic and mixed episodes of bipolar I disorder, and as maintenance therapy in bipolar I disorder when added to lithium or valproate. There is also an intramuscular injection form used in the clinic or emergency setting for acute agitation associated with schizophrenia. This guide focuses on the oral forms used day to day.

Ziprasidone is often chosen when metabolic side effects are a specific concern, for example, in someone with a strong family history of diabetes, existing weight concerns, or metabolic changes on a previous antipsychotic. The trade-off is that it requires taking it with food, which is a real day-to-day commitment.

How it works

Ziprasidone is an atypical antipsychotic. It works on the brain's dopamine and serotonin systems, dampening dopamine signaling in the circuits linked to psychosis and mania while modulating serotonin activity that helps soften the movement side effects of pure dopamine blockade. That combined action is the shared mechanism of the atypical class.

Ziprasidone has a broader receptor profile than most atypicals, touching several serotonin receptor subtypes and also mildly affecting serotonin and norepinephrine reuptake. How much those extra actions matter clinically is not entirely settled, but they are part of why its side-effect fingerprint is different from other antipsychotics.

Receptor mechanism (detail)

Ziprasidone is a D2 and 5-HT2A antagonist with 5-HT1A partial agonist activity and mild inhibition of serotonin and norepinephrine reuptake (SERT and NET). In plain terms, it blocks the overactive dopamine signal that drives psychosis and mania and the serotonin receptor that helps prevent movement side effects, while the 5-HT1A partial agonist activity and the mild reuptake effects give it some antidepressant-like character. It has relatively low affinity at histamine H1 and muscarinic receptors, which is one reason weight gain and dry mouth are less prominent than with, for example, olanzapine or quetiapine.

Potency and typical dosing pattern

Ranges are typical framework only, not a prescription for any individual. Ziprasidone is moderate-potency by milligram and is dosed twice daily.

For schizophrenia, a common starting dose is 20 to 40 mg twice daily, with a usual range of 80 to 160 mg per day divided into two doses. For bipolar mania, starting is often 40 mg twice daily on day one, 60 to 80 mg twice daily on day two, then adjusted to a usual range of 80 to 160 mg per day. Ziprasidone must be taken with a meal of at least 500 kilocalories, otherwise absorption drops by roughly 50 percent, and blood levels can be too low to work. The prescriber sets and adjusts the dose based on response, side effects, and other medications.

Safety monitoring

• ECG. A baseline ECG and periodic ECGs are common with ziprasidone, because it can prolong the QTc interval on the heart tracing. It is avoided or reconsidered when the QTc is greater than 500 ms, when a person is on other QT-prolonging medications, or when potassium or magnesium levels are low.
• Metabolic labs. Weight and BMI at baseline, weeks 4, 8, and 12, then quarterly. Fasting glucose or HbA1c and a lipid panel at baseline, three months, and at minimum annually. Ziprasidone is metabolically friendlier than olanzapine or quetiapine, but monitoring is still standard.
• Movement effects. Ask about akathisia (restlessness) and stiffness at every early visit. An involuntary-movement screen (AIMS) every six months looks for tardive dyskinesia over the long term.
• Electrolytes. Potassium and magnesium may be checked, especially if the person is on diuretics or has vomiting or diarrhea.
• Blood pressure at baseline and periodically.

Metformin co-commencement. Aoife Carolan / Schizophrenia Bulletin guideline.

A clinical guideline led by Aoife Carolan strongly recommends co-commencing metformin alongside high-risk antipsychotics like olanzapine or clozapine. This proactive approach helps mitigate severe metabolic side effects, significantly reducing antipsychotic-induced weight gain and improving insulin resistance. The Schizophrenia Bulletin guideline states that when prescribing olanzapine or clozapine, metformin should be initiated immediately to prevent weight gain and cardiometabolic issues. Ziprasidone is lower metabolic risk in the guideline; metformin is recommended when other cardiometabolic conditions are present, and metformin should be started if weight rises by more than 3 percent of pre-medication weight.

Typical titration used in the guideline: 500 mg once daily → 500 mg twice daily after one week → 500 mg increments every two weeks as tolerated → up to 1000 mg twice daily by about week six. Contraindicated with eGFR below 30 mL/min/1.73 m²; renal function is checked annually and metformin is held during acute illness or dehydration.

Source: Carolan A, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin. 2025;51(5):1193 to 1203.

What to expect

Common side effects

Most people get some side effects. The common ones include:

• Sedation, especially early on.
• Restlessness or an inability to sit still, akathisia.
• Stiffness, tremor, or slowed movement.
• Nausea, sometimes helped by taking it with a slightly larger meal.
• Headache.
• Dizziness or lightheadedness on standing.

Akathisia and stiffness are treatable and worth flagging early. Many of the milder early effects ease within the first weeks. If a side effect is severe, or it is not improving, that is a conversation to have with the prescriber rather than a reason to stop on your own.

Serious side effects and warnings

Serious problems are uncommon, but a few are worth knowing.

Boxed warning. Like all antipsychotics, ziprasidone carries an FDA boxed warning that it increases the risk of death in older adults with dementia-related psychosis, and antipsychotics are not approved for that use.

• QTc prolongation. Ziprasidone can lengthen a specific interval on the heart tracing called the QTc. In rare cases this can cause a dangerous rhythm. Because of this, ziprasidone is generally avoided with other QT-prolonging medications, with a history of certain arrhythmias, or with low potassium or magnesium. This is the reason for periodic ECG monitoring.
• Tardive dyskinesia. A movement disorder linked to long-term antipsychotic use, involving repetitive involuntary movements, often of the face or mouth. The risk rises with longer use.
• Neuroleptic malignant syndrome. A rare but serious reaction. Signs include high fever, muscle stiffness, confusion, and an unstable heartbeat or blood pressure. It is a medical emergency.
• Rash. A rash (including in rare cases DRESS syndrome) has been reported and should be discussed with a clinician promptly.

Sexual side effects

Ziprasidone has a lower rate of sexual side effects than several other antipsychotics, in part because it raises prolactin less than risperidone and paliperidone. Reduced desire or difficulty with arousal are still possible for some people. If that happens, it is worth raising with a prescriber rather than living with it, because there are usually options.

Weight, appetite, and sleep

Ziprasidone is one of the more weight-neutral antipsychotics. Some people gain a small amount of weight, but on average the effect is smaller than with olanzapine or quetiapine, and blood sugar and cholesterol tend to be less affected. Weight, blood sugar, and cholesterol are still checked periodically. Sedation is common early on but often eases; if daytime sedation is a problem, that is worth discussing with the prescriber.

Starting and dosing basics

This section is general background, not a dosing instruction for any individual. The right dose is a decision for a prescriber.

Ziprasidone comes as capsules taken by mouth twice daily. Each dose must be taken with a meal of at least 500 kilocalories. A snack or a small meal is not enough, the difference in absorption is large. Many people take it with breakfast and dinner as a routine that matches meals they were already eating. The prescriber starts at a modest dose and adjusts it gradually based on how a person responds and tolerates it.

Missed doses and interactions

If you miss a dose, the general guidance is to take it when you remember, unless it is almost time for the next dose. In that case, skip the missed dose and carry on. Don't take two doses to make up for one.

Ziprasidone should not be combined with other medications that prolong the QTc interval, the prescriber and pharmacist need a full list of your medications and supplements, including over-the-counter ones, so this can be checked. Some antifungals, some antibiotics, some antiarrhythmics, and methadone are examples of medications that need careful review. Alcohol is not formally prohibited, but it can worsen sedation and is generally best limited.

Stopping and tapering

Stopping ziprasidone should be gradual and planned with a prescriber. The body adjusts to the medication over time, and stopping suddenly can cause a return of symptoms. A prescriber can step the dose down over time in a way that fits the situation. Deciding to stop because you feel better is understandable, but it is still worth doing slowly and with guidance.

Pregnancy and breastfeeding

This is an area where individual circumstances matter and the decision belongs with a clinician. Untreated psychosis and bipolar disorder carry their own significant risks during pregnancy, and ziprasidone also passes into breast milk. None of that adds up to one answer that fits everyone. Anyone who is pregnant, planning a pregnancy, or breastfeeding should talk it through with their prescriber so the specific risks and benefits can be weighed for their situation. This is not medical advice.

Cost and generic availability

Ziprasidone has been available as a generic for years and is moderately priced. The brand name Geodon and generic ziprasidone contain the same active medication and work the same way. Most insurance plans cover the generic capsules.

Common questions

Why do I need to take it with food? Ziprasidone's absorption depends heavily on food. Without a meal of at least about 500 kilocalories, roughly half of the dose can fail to be absorbed, and blood levels drop too low to work. Taking it with two real meals a day, typically breakfast and dinner, is what makes it effective. This is one of the more strict food requirements in psychiatry.

What is QT prolongation? The QTc is a measurement of how long it takes the heart's electrical system to reset between beats. Some medications, including ziprasidone, can lengthen that interval slightly. In rare cases, especially when combined with other QT-prolonging drugs or with low potassium or magnesium, this can trigger a dangerous heart rhythm. Baseline and periodic ECGs, and careful review of other medications, are what keep this manageable.

Why is it metabolically better than olanzapine? Ziprasidone has much lower activity at the histamine and serotonin receptors that seem to drive antipsychotic weight gain. On average, people gain much less weight on ziprasidone than on olanzapine, and shifts in blood sugar and cholesterol tend to be smaller too. That is a real advantage, especially in someone with existing metabolic risk.

Will it make me gain weight? On average, weight change on ziprasidone is small, and some people do not gain any. It is one of the more weight-neutral antipsychotics. Weight, blood sugar, and cholesterol are still monitored.

Do I really need an ECG? For most people starting ziprasidone, yes, at least a baseline. It is a straightforward test that lets the prescriber confirm the QTc is safe to start and gives a comparison point later if other QT-prolonging medications are added.

Questions to ask your prescriber

• What are we hoping this treats, and how will we know it's working?
• What counts as a "meal" for the food requirement, and what do I do if I can't eat?
• Which side effects should I expect early, and which ones should I call about?
• Do I need an ECG before starting, and how often after that?
• If we decide to stop it later, how would we do that safely?

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes, and current as of June 8, 2026.

• U.S. Food and Drug Administration. Prescribing information (DailyMed).
• MedlinePlus, U.S. National Library of Medicine.
• National Institute of Mental Health.
• American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia, 3rd edition.
• National Institute for Health and Care Excellence (NICE). CG178, Psychosis and schizophrenia in adults.
• American Diabetes Association / American Psychiatric Association. Consensus Statement on Antipsychotic Drugs and Obesity and Diabetes.
• Carolan A, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin. 2025;51(5):1193 to 1203.